This federal contract award to RLS (USA) Inc., a foreign-owned for-profit radiopharmacy company, is for the provision of radiopharmaceuticals and related supplies to the U.S. Department of Veterans Affairs (VA) and the Defense Health Agency (DHA). The contract has a ceiling value of $179,605.38 and a performance period through March 31, 2026.
RLS (USA) Inc. operates 31 radiopharmacy facilities across 18 states, enabling it to efficiently deliver time-sensitive radiopharmaceutical products to various government healthcare facilities nationwide. The company holds several federal contract Indefinite Delivery Vehicles (IDVs) with the VA and DHA, including a $4,998,603.38 contract with VA VISN 17 for radiopharmaceuticals, a $538,493.10 small business set-aside contract with VA VISN 2 for Netspot (Gallium-68 dotatate), and a $1,914,116.40 contract with the DHA for general radiopharmaceuticals. These IDVs facilitate the regular supply of critical radiopharmaceutical products, such as gallium-67, fluorodeoxyglucose F-18, thallium-201, technetium-99m, and Gallium-68 Dotatate, to support nuclear medicine diagnostic services at VA medical centers and military treatment facilities.
Generated 12/12/24, 9:40 AM